Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Avidity Biosciences Q3 EPS $(1.27) Misses $(1.11) Estimate, Sales $12.475M Beat $1.932M Estimate

Author: Benzinga Newsdesk | November 10, 2025 04:24pm
Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(1.11) by 13.9 percent. This is a 95.38 percent decrease over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $12.475 million which beat the analyst consensus estimate of $1.932 million by 545.65 percent. This is a 434.03 percent increase over sales of $2.336 million the same period last year.

Posted In: RNA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist